Nestlé Health Science Completes Investment in Seres Health
Nestlé Health Science has completed a SFr65.6 million (Eur54.6 million) investment in Seres Health Inc. Seres Health, based in Cambridge, Massachusetts, USA, is a leading microbiome therapeutics company that is developing a novel class of biological drugs designed to treat diseases by restoring the function of the microbiome. The microbiome consists of around 100 trillion microorganisms that live in the body and perform a variety of functions, including supporting the immune system.
The investment is aligned with Nestlé Health Science’s ambition to advance the role of novel therapeutics in health care by leveraging external investment opportunities.
In addition to the investment in Seres Health, Nestlé Health Science has entered into a strategic innovation partnership with Flagship Ventures, a leading venture capital and venture creation firm focused on innovations in healthcare and sustainability. Flagship Ventures is based in Cambridge, Massachusetts, USA.
